Lupin, a pharmaceutical company, plans to enter the digital healthcare space in India by launching cardio-vascular therapeutics in 10 cities by February.
Delhi, Mumbai, Kolkata, Chennai, Bengaluru, Hyderabad, Ahmedabad, Jaipur, Pune, and Vijayawada are among the cities. The move comes a year and a half after the company announced its intention to enter the digital space in June 2021, and it involves the establishment of a new subsidiary, Lupin Digital Health. “Cardiovascular therapy accounts for 25% of our India business.” So far, digital therapeutics in India have been focused on wellness and diabetes management. The company’s entry into the cardio-vascular segment will be novel.
According to the company, its services will be based on monitoring, adherence, and awareness. They will include accurate monitoring devices, real-time updates of vital parameters, timely alerts of out-of-range readings, reminders to schedule doctor appointments, expert advice, a health mall for medicine and lab tests, and educational modules.
Lupin will initially focus on the ACS (acute coronary syndrome) space, later expanding to heart failure and hypertension in the cardio-vascular space. “Once we complete the cardio-vascular space, we will move on to other chronic diseases such as mental illness and respiratory issues,” Lupin Digital Health said. The company intends to expand its digital therapeutics services to approximately 28-30 cities by the end of the following calendar year.